华海药业：左卡尼汀注射液获得药品注册证书

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of L-carnitine injection, which is intended for patients with chronic renal failure undergoing long-term hemodialysis and suffering from secondary carnitine deficiency-related complications [1] Group 1 - The L-carnitine injection is used to address complications such as cardiomyopathy, skeletal muscle disease, arrhythmias, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The company has invested approximately 4.69 million yuan in the research and development of the L-carnitine injection project [1]